15% OFF $150+· CodeFALL15
Ends October 15Shop now
Lot certificates published
Discreet shipping

Compound monograph

Liraglutide

Liraglutide is an acylated peptide analog of glucagon-like peptide-1, characterized against the GLP-1 receptor.

Published: 2026-09-04Literature/identifier verification: 2026-08-23

01

Identity & nomenclature

Liraglutide is an acylated peptide analog of glucagon-like peptide-1, characterized against the GLP-1 receptor.

PubChem lists NN2211 as a development identifier for the liraglutide molecular record.

Declared aliases and development codes: NN2211.

02

Molecular properties

Molecular formulaC172H265N43O51
Molecular mass3751 Da
CAS Registry Number204656-20-2
PubChem CID16134956
UNII839I73S42A

03

Structural characteristics

Built on the GLP-1(7-37) scaffold by a different strategy from semaglutide. Using native GLP-1 numbering, alanine 8 is retained, lysine 34 becomes arginine, and the lysine 26 side chain carries a C16 palmitoyl group through a single gamma-glutamyl spacer. Semaglutide's position-8 substitution and its longer diacid and spacer are not features of liraglutide. The related GLP-1(7-37) entry identifies the native structural parent. Receptor-dependence work using fluorescently labeled liraglutide reported binding within circumventricular organs and uptake into arcuate nucleus neurons expressing proopiomelanocortin and cocaine- and amphetamine-regulated transcript. Binding was not observed in GLP-1 receptor knockout mice, establishing that brain uptake in that model was receptor-dependent.

04

Molecular targets & mechanisms

05

Analytical considerations

Identity assessment must account for both the peptide backbone and the acyl modification represented in the PubChem molecular record, as for other acylated GLP-1 analogs in this library.

06

Verified bibliography

  1. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.

    Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, Hansen G, Grove KL, Pyke C, Raun K, Schäffer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Bjerre Knudsen L

    The Journal of clinical investigation · 2014-09-09 · Journal Article

    current
  2. Pharmacology, physiology, and mechanisms of incretin hormone action.

    Campbell JE, Drucker DJ

    Cell metabolism · 2013-05-16 · Review

    current
  3. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein.

    Zhang Y, Sun B, Feng D, Hu H, Chu M, Qu Q, Tarrasch JT, Li S, Sun Kobilka T, Kobilka BK, Skiniotis G

    Nature · 2017-05-24 · Journal Article

    current
  4. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.

    Kawai T, Sun B, Yoshino H, Feng D, Suzuki Y, Fukazawa M, Nagao S, Wainscott DB, Showalter AD, Droz BA, Kobilka TS, Coghlan MP, Willard FS, Kawabe Y, Kobilka BK, Sloop KW

    Proceedings of the National Academy of Sciences of the United States of America · 2020-11-11 · Journal Article

    current
  5. Structural basis for ligand recognition of incretin receptors.

    Underwood CR, Parthier C, Reedtz-Runge S

    Vitamins and hormones · 2010 · Review

    current

10

Methodology & citation verification

Reference identity is checked against official PubMed metadata. Local deterministic receipts bind each normalized title and canonical metadata record to its verification date. Scientific values remain absent when an authoritative source has not been verified.

Read the full methodology →